Abbott Laboratories stock (US0028241000): focus on valuation as regulatory AI approvals frame growth story

Abbott Laboratories shares on the NYSE trade against a backdrop of fresh US and European regulatory clearances for an AI-assisted coronary imaging platform and a dual glucose-ketone sensor, keeping attention on how the market values the US medtech group after its latest quarterly results.

Abbott Laboratories shares on the New York Stock Exchange remain in focus for US investors as the healthcare group continues to build on recent regulatory milestones for its cardiology and diabetes technology platforms, including new approvals in the United States and Europe for an AI-assisted coronary imaging solution and a dual glucose-ketone sensor, developments that frame current valuation debates after the latest earnings release, according to company statements and financial press reports as of 05/2026.

The stock, which trades under the ticker ABT on the NYSE in the United States, has been reacting to a series of product and regulatory updates that underline the company’s push in diagnostics, cardiovascular devices and diabetes care, with analysts and market data providers closely watching how these developments feed into earnings expectations and multiples that investors are willing to pay for the US-based medtech name.

As of: 05/29/2026

By the editorial team - specialized in equity coverage.

At a glance

• Name: Abbott Laboratories
• Sector/industry: Healthcare equipment, medical devices and diagnostics
• Headquarters/country: Abbott Park, United States
• Core markets: North America, Europe, Asia-Pacific and Latin America
• Key revenue drivers: Cardiovascular and neuromodulation devices, diabetes care systems, diagnostics and nutrition products
• Home exchange/listing venue: New York Stock Exchange (ABT)
• Trading currency: USD

Abbott Laboratories: core business model

Abbott Laboratories operates as a diversified healthcare technology group that develops, manufactures and sells medical devices, diagnostics, nutrition products and branded generic medicines, with revenue primarily driven by demand for its cardiovascular and neuromodulation devices, diabetes monitoring systems, core laboratory diagnostics and nutritional brands across major global markets.

Valuation metrics and multiples for Abbott Laboratories

On recent valuation screens from major financial data providers in May 2026, Abbott Laboratories has typically traded at a price-to-earnings ratio in the low-to-mid 20s based on forward 12-month earnings estimates, placing the US medtech group at a premium to some broader market indices but broadly in line with large-cap medical technology peers that also derive a significant portion of their revenue from recurring device and diagnostic sales.

Enterprise-value-to-EBITDA multiples for Abbott Laboratories, again using May 2026 consensus estimates, tend to cluster in the mid-teens, reflecting expectations for continued growth in key franchises such as cardiovascular devices and diabetes care following recent regulatory clearances for AI-enabled coronary imaging and glucose-ketone sensing, while the dividend yield, based on the company’s declared annual payout and contemporaneous share price data in 2026, usually sits in the low single digits, underscoring a balance between income and growth characteristics in the current market valuation of the US-listed stock.

Conclusion

Current trading in Abbott Laboratories on the New York Stock Exchange is shaped by the company’s ongoing rollout of new medical technologies, including AI-assisted coronary imaging and advanced diabetes monitoring, as well as by investor assessments of how these innovations support earnings growth and justify prevailing valuation multiples.

With price-to-earnings and enterprise-value-to-EBITDA ratios that align with other large US medtech names, the stock’s profile in 2026 reflects expectations for steady expansion in core cardiovascular, diagnostics and diabetes franchises, while its dividend yield and diversified business mix remain central to how the market in the United States and beyond values the shares.

Disclaimer: This article does not constitute investment advice. The comprehensive scope of this informative article was made possible through the use of a.i.. Stocks are volatile financial instruments.